Short communicationIn vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers
References (14)
- et al.
Normal human serum contains two forms of acetylcholinesterase
Clin Chim Acta
(1986) - et al.
A specific radioisotopic assay for acetylcholinesterase and pseudo-cholinesterase in brain and plasma
Biochem Med
(1969) - et al.
Acetyl- and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease
J Neurol Sci
(1987) - et al.
Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo
Life Sci
(1990) - et al.
Effects of persistent selective suppression of ganglionic butyrylcholinesterase on steady state and regenerating levels of acetylcholinesterase: implications regarding function of butyrylcholinesterase and regulation of protein synthesis
- et al.
De novo amplification within a ‘silent’ human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides
- et al.
iso-OMPA-induced potentiation of soman toxicity in rat
Arch Toxicol
(1987)
Cited by (83)
Anti-cholinergic activities of Turkish Corydalis DC. species
2021, Phytochemistry LettersEvaluation of some biological activities of the tubers of Corydalis solida (L.) Clairv. ssp. incisa Liéden growing in Turkey
2019, South African Journal of BotanyCitation Excerpt :Galantamine increases the availability of ACh in the cholinergic synapse by competitively inhibiting the enzyme responsible for its breakdown, AChE. The binding of galantamine to AChE slows down the catabolism of ACh and, as a result, ACh levels in the synaptic cleft are increased (Thomsen et al., 1991a,b; Bores et al., 1996; Heinrich and Teoh, 2004). Therefore, current drug therapies are based on the cholinergic hypothesis.
Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling
2019, Biomedicine and PharmacotherapyCitation Excerpt :The aforementioned study assessing AChE activity [45] has not reported EC50 estimates; plasma concentrations were lower than in our study and maximum enzyme inhibition did not exceed 35%. However, data from ex vivo inhibition of human erythrocytes, incubated with physostigmine, suggested an EC50 in the range of 6.7–7.4 ng/mL [55,56], which is in line with our findings. Plasma concentrations resulting from physostigmine salicylate infusion (initial bolus and continuous infusion) in patients with septic shock were found to be sufficient for about 50%–70% inhibition of erythrocyte AChE activity.
Interaction between substrates suggests a relationship between organophosphorus-sensitive phenylvalerate- and acetylcholine-hydrolyzing activities in chicken brain
2014, Toxicology LettersCitation Excerpt :PMSF resistant PVase activity was also resistant to the inhibition by BW284C51 (a typical specific reversible inhibitor of AChE in mammals; Fig. 6), but BuChE inhibitors as ethopropazine (a reversible inhibitor) and iso-OMPA (an irreversible inhibitor) inhibited the PMSF resistant PVase activity. The inhibition by iso-OMPA was time progressive (Fig. 7), which indicates that this inhibition can be irreversible and it matches with the results obtained for human BuChE (Thomsen et al., 1991). Some authors have previously used these specific inhibitors in order to isolate and purify AChE (Rotundo, 1984) and BuChE (Treskatis et al., 1992) of chicken brain but in membrane fraction.
Role of acetylcholinesterase inhibitors and alzheimer disease
2014, Drug Design and Discovery in Alzheimer's DiseaseThe geographic isolation of Leucojum aestivum populations leads to divergation of alkaloid biosynthesis
2013, Biochemical Systematics and EcologyCitation Excerpt :It is gathered from the natural habitats for industrial purposes which causes increasing problems with depletion of the wild populations. Galanthamine, a reversible acetylcholinesterase (AChE) inhibitor, is marketed as a hidrobromide salt under the name of Razadine® (formerly Reminyl®) for the treatment of Alzheimer's disease (Thomsen et al., 1991). According to data presented by the Alzheimer's Association (2010) the prevalence of Alzheimer's disease will quadruple by 2050.